Broad-Spectrum Antiviral Therapeutics
(A) 100 nM DRACOs were effective against 50 pfu/well encephalomyelitis. Cell viability measured 6 dpi showed little difference if DRACO-containing medium was removed 3 dpi when untreated cells had widespread CPE; there was no relapse of viral CPE in treated cells after DRACOs were withdrawn. (B) 100 nM PTD-PKR-Apaf DRACO was effective if added before, simultaneously with, or up to at least 6 hours after encephalomyelitis. (C) Multiple 100 nM DRACOs were effective against 50 pfu/well murine encephalomyelitis (4 dpi). Even better performance of these alternate DRACOs might be achieved with further optimization.